PD-1 immunology in the kidneys: a growing relationship

Front Immunol. 2024 Oct 23:15:1458209. doi: 10.3389/fimmu.2024.1458209. eCollection 2024.

Abstract

In recent years, knowledge regarding immune regulation has expanded rapidly, and major advancements have been made in immunotherapy for immune-associated disorders, particularly cancer. The programmed cell death 1 (PD-1) pathway is a cornerstone in immune regulation. It comprises PD-1 and its ligands mediating immune tolerance mechanisms and immune homeostasis. Accumulating evidence demonstrates that the PD-1 axis has a crucial immunosuppressive role in the tumor microenvironment and autoimmune diseases. PD-1 receptors and ligands on immune cells and renal parenchymal cells aid in maintaining immunological homeostasis in the kidneys. Here, we present a comprehensive review of PD-1 immunology in various kidney disorders, including renal cell carcinoma, glomerulonephritis, kidney transplantation, renal aging, and renal immune-related adverse events secondary to PD-1 immunotherapy.

Keywords: glomerulonephritis; immune-related adverse events; kidney transplantation; programmed death 1; programmed death ligand 1; renal aging; renal cell carcinoma.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy / methods
  • Kidney Diseases* / immunology
  • Kidney Neoplasms / immunology
  • Kidney Neoplasms / therapy
  • Kidney* / immunology
  • Kidney* / metabolism
  • Kidney* / pathology
  • Programmed Cell Death 1 Receptor* / immunology

Substances

  • Programmed Cell Death 1 Receptor
  • PDCD1 protein, human
  • Immune Checkpoint Inhibitors